Welcome to our dedicated page for LENZ THERAPEUTICS SEC filings (Ticker: LENZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech disclosures are notoriously dense, and LENZ Therapeutics’ SEC reports are no exception. Ten-Ks stuffed with Phase 3 trial protocols, 10-Qs detailing cash runway, and sudden 8-Ks about FDA feedback can leave investors scrolling EDGAR asking, “How do I decode LENZ Therapeutics SEC filings explained simply?”
Stock Titan bridges that gap. Our platform layers AI-powered summaries and plain-language annotations on every document, turning 200-page reports into actionable briefs. Need the LENZ Therapeutics quarterly earnings report 10-Q filing before markets open? It appears in real time, already tagged with key metrics. Want the LENZ Therapeutics insider trading Form 4 transactions feed? We stream LENZ Therapeutics Form 4 insider transactions real-time so you can track executive moves the moment they hit EDGAR.
Why focus on LENZ? Because each filing can shift expectations for its aceclidine eye-drop. Our AI highlights:
- R&D spend versus cash reserves for a clear runway snapshot
- Regulatory milestones tucked deep in the LENZ Therapeutics annual report 10-K simplified
- Board pay packages inside the LENZ Therapeutics proxy statement executive compensation
- Material developments, like trial readouts, in LENZ Therapeutics 8-K material events explained
- LENZ Therapeutics executive stock transactions Form 4 with context on option grants and sales
Whether you’re understanding LENZ Therapeutics SEC documents with AI for diligence or seeking a quick LENZ Therapeutics earnings report filing analysis, Stock Titan delivers concise insights, expert commentary and real-time alerts—so you spend minutes, not hours, mastering the details that drive valuation.
Amendment No. 7 to a Schedule 13D reports ownership and recent sales of LENZ Therapeutics, Inc. common stock by multiple Versant-related entities. The filing lists Versant Venture Capital VI, L.P. (Versant VI) as holding 1,400,220 shares, representing 4.9% of the outstanding shares (based on 28,522,096 shares reported as of July 24, 2025). Versant Vantage II, L.P. holds 842,162 shares (3.0%). Versant Venture Capital VII, L.P. holds 1,033,412 shares (including a warrant for 70,534 shares), representing 3.6% on an adjusted basis.
The Amendment discloses share sales: on August 15, 2025 Versant VI sold 145,051 shares at $39.50 per share (proceeds ~$5,729,514.50) and Versant VII sold 69,949 shares at $39.50 (proceeds ~$2,762,985.50). On August 18, 2025 Versant VI sold 30,628 shares at a weighted average $38.5611 (proceeds ~$1,181,049.37) and Versant VII sold 15,085 shares at the same weighted average (proceeds ~$581,694.19). The Amendment updates cover-page holdings and clarifies related general partner relationships; other items from the original Schedule 13D remain unchanged.
Versant-affiliated investment vehicles reported multiple sales of LENZ Therapeutics common stock in mid-August 2025. Versant Venture Capital VI, L.P., Versant Venture Capital VII, L.P. and Versant Vantage II, L.P. sold a total of 260,713 shares across transactions dated 08/15/2025 and 08/18/2025 at prices ranging from $38.26 to $39.50 (a weighted average price reported for some sales as $38.5611). After the reported disposals, the filing shows Versant Venture Capital VI beneficially owned 1,430,848 shares (direct) and 977,963 shares (indirect) in related accounts; Versant Vantage II and affiliated entities reported 842,162 shares (indirect). The filing includes customary disclosure of the general partner/GP-GP structure and disclaimers of beneficial ownership except for pecuniary interests.
LENZ Therapeutics, Inc. (LENZ) – Form 4 insider transaction filed 07/01/2025
Versant Venture Capital VI, L.P. (together with affiliated Versant entities, a >10% beneficial owner of LENZ) reported the sale of 200,000 LENZ common shares on 06/27/2025 at a weighted-average price of $30.465 per share (price range $30.18–$30.75). Following the disposition, the filing shows:
- Direct ownership by Versant Venture Capital VI of 1,767,275 shares.
- Indirect ownership of 1,047,912 shares through Versant Venture Capital VII, L.P. (footnote 3).
- Indirect ownership of 842,162 shares through Versant Vantage II, L.P. (footnote 4).
The aggregate direct sale represents roughly 10.2% of Versant VI’s reported direct holdings before the transaction (calculation assumes no other changes) and signals the first disclosed disposition by the Versant funds in 2025. No derivative security activity was reported. The entities remain above the 10% ownership threshold and continue to have board representation.
Amendment No. 5 to Schedule 13D discloses the current ownership position of several Versant-affiliated investment vehicles in LENZ Therapeutics, Inc. ("LENZ") common stock.
The filing, dated 20 June 2025, lists six related reporting persons:
- Versant Venture Capital VI, L.P. ("Versant VI")
- Versant Ventures VI GP, L.P.
- Versant Ventures VI GP-GP, LLC
- Versant Vantage II, L.P. ("Vantage II")
- Versant Vantage II GP, L.P.
- Versant Vantage II GP-GP, LLC
Key beneficial ownership details are as follows:
- Versant VI: 1,967,275 shares with 7.0 % of outstanding common stock. The fund holds sole voting and dispositive power over the shares.
- Vantage II: 842,162 shares with 3.0 % of outstanding common stock. The fund also exercises sole voting and dispositive power.
Collectively, the two primary funds report 2,809,437 shares, equating to roughly 10 % of LENZ’s 28,146,154 shares outstanding (per the company’s Form 10-Q filed 7 May 2025). Control of the shares flows through the respective general partners and managing entities, which are therefore shown with shared voting and dispositive powers.
No financing source other than working capital ("WC") for the limited partnerships and affiliate funds ("AF") for the GP entities is cited, and the amendment does not disclose any legal proceedings. The filing provides no narrative on investment intent, purchase or sale transactions, or future plans; it simply updates ownership percentages and capital structure references.
For investors, the disclosure confirms that Versant remains a significant, though non-controlling, strategic shareholder in LENZ. There are no explicit signals of activist activity or immediate liquidity events contained in this amendment.
Form 4 highlights for LENZ Therapeutics, Inc. (LENZ) filed 20-Jun-2025:
Multiple Versant Venture–affiliated funds, each classified as a 10% beneficial owner, reported open-market sales of LENZ common stock on 18-Jun-2025 and 20-Jun-2025.
- 18-Jun-2025: Versant Venture Capital VII, L.P. (indirect holding) sold 100,000 shares at $29.95.
- 20-Jun-2025: The same fund sold an additional 100,877 shares at $30.35.
- 20-Jun-2025: Versant Venture Capital VI, L.P. (direct holding) sold 133,924 shares at $30.25.
Total shares disposed across the two trading days amount to 334,801 shares, representing gross proceeds of roughly $10.1 million based on the stated sale prices.
Post-sale ownership:
- Versant Venture Capital VII, L.P. now holds 1,047,912 shares (indirect).
- Versant Venture Capital VI, L.P. now holds 1,967,275 shares (direct).
- Versant Vantage II, L.P. continues to hold 842,162 shares (indirect, no new transactions).
All reporting entities remain above the 10 % threshold and continue to be classified as insiders. No derivative transactions were reported. The filing does not disclose reasons for the sales or any 10b5-1 trading plan reliance, therefore investors should interpret the activity strictly as open-market disposals by a significant shareholder.
FAQ
What is the current stock price of LENZ THERAPEUTICS (LENZ)?
What is the market cap of LENZ THERAPEUTICS (LENZ)?
